This is an epidemiologic study. No arms are considered.

Age-related Macular Degeneration

Patients will collect blood and urine for metabolome analysis

Blood draw and urine collection

Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration

The hypothesis is that AMD-progressors present a distinct plasma and urine metabolomic profile. For this, metabolites in blood and plasma will be detected in order to determine the metabolome profile.Non-targeted MS analysis will be performed using Ultrahigh Performance Liquid Chromatography-Tandem MS (measurement tool).

Our hypothesis is that the statistical comparison of the metabolic profiles of AMD-progressors with those of the corresponding final disease stage will allow the identification of potential biomarkers of progression. These may either comprise features (sets of metabolites) common to both groups or distinct features which will form a particular progressors signature.

Association for Innovation and Biomedical Research on Light and Image

tauroursodeoxycholic acid di-hydrate
tauroursodeoxycholic acid (TUDCA): Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year

TUDCA

excipient lactose
Placebo: identical placebo by oral route at the same dosing schedule

Placebo

Total

Sex: Female, Male

Region of Enrollment

Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period.

excipient lactose
Placebo: identical placebo by oral route at the same dosing schedule composed of excipient lactose

The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.

Forced Vital Capacity (FVC) %

SF-36 Quality of Life Rating Scale

Time to Tracheostomy From Starting of Study Medication Dosing (if Appropriate)

Survival Time From Starting of Study Medication Dosing (if Appropriate)

ALSFRS-R at Study End

laboratory tests, patients' reports and the investigator's judgments

Incidence and Severity of Adverse Events, and Their Relationship to Treatment

Medical Research Council Scores for Right and Left Muscle Groups

Overall Study

Alberto Albanese

Amyotrophic Lateral Sclerosis

Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year

tauroursodeoxycholic acid (TUDCA)

identical placebo by oral route at the same dosing schedule

Fondazione IRCCS Istituto neurologico Carlo Besta

Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis

taurine/атрофия

Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration

Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

Самая полная база данных о лекарственных травах, подтвержденная наукой